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The influence of metabolic syndrome on
hemodialysis access patency
Clinton D. Protack, MD,a Akhilesh Jain, MD,a Penny Vasilas, RN,b and Alan Dardik, MD, PhD,a,b
New Haven and West Haven, Conn
Objective: The natural history of patients with metabolic syndrome (MetS) undergoing hemodialysis access placement is
unknown. MetS has previously been found as a risk factor for poor outcomes for vascular surgery patients undergoing
other interventions. The aim of this is study is to describe the outcomes of MetS patients undergoing primary
hemodialysis access placement.
Methods: The medical records of the 187 patients who underwent hemodialysis access placement between 1999 and 2009
at the Veterans Administration Connecticut Healthcare System were reviewed. Survival, primary patency, and secondary
patency were evaluated using the Gehan-Breslow test for survival. MetS was defined as the presence of three or more of
the following: blood pressure >130/90 mm Hg; triglycerides >150 mg/dL; high-density lipoprotein <50 mg/dL for
women and <40 mg/dL for men; body mass index >30 kg/m2; or fasting blood glucose >110 mg/dL.
Results:Of the 187 patients who underwent hemodialysis access placement, 115 (61%) were identified to have MetS. The
distribution of MetS factors among all patients was hypertension in 98%, diabetes in 58%, elevated triclyceride in 39%,
decreased high-density lipoprotein in 60%, elevated body mass index in 36%, and 39% were currently receiving
hemodialysis. Patients were a mean age of 66 years. The median length of follow-up was 4.2 years. The forearm was site
of fistula placement in 53%; no difference existed between groups (MetS, 57%; noMetS, 50%; P .388). The median time
to primary failure was 0.46 years for all patients (MetS, 0.555 years; no MetS, 0.436 years; P .255). Secondary patency
was 50% at 1.18 years for all patients (no MetS, 1.94 years; MetS, 0.72 years; P .024). Median survival duration for all
patients was 4.15 years (no MetS, 5.07 years; MetS, 3.63 years; P  .019).
Conclusions: MetS is prevalent among patients undergoing hemodialysis access placement. Patients with MetS have
equivalent primary patency rates; however, their survival and cumulative patency rates are significantly lower than in
patients without MetS. Patients with MetS form a high-risk group that needs intensive surveillance protocols. ( J Vasc
Surg 2012;56:1656-62.)
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oRenal disease in the United States is prevalent, morbid,
costly, and associated with significant mortality.1,2 Autog-
enous arteriovenous (AV) fistula (AVF) placement affords
the most durable and preferred mode of access for hemo-
dialysis. However, despite the superior results of AVFs
compared with the alternatives, AVFs fail to mature in 20%
to 50% of patients and posses early failure rates, with a
1-year primary patency of 60% to 65%.3
Metabolic syndrome (MetS) consists of atherogenic
dyslipidemia, hypertension, hyperglycemia, a prothrom-
botic state, and a proinflammatory state,4 and affects 20% to
30% of the overall population.5 The Framingham Heart
Study found the prevalence of MetS doubled during a
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16560-year period and was associated with a 2.36-fold in-
reased rate of cardiovascular events and a threefold in-
reased risk in death.6 Patients with MetS have been shown
o have unfavorable perioperative outcomes for cardiovas-
ular7 and peripheral vascular interventions,8,9 as well as for
onvascular operations.10 MetS increases the risk of post-
perative saphenous vein graft occlusion and the develop-
ent of a significant lesion after coronary artery bypass
rafting.11
Although patients with lipid abnormalities12 and dia-
etes mellitus (DM)13 have been identified as having
reater rates of access dysfunction, surprisingly, the influ-
nce of MetS on hemodialysis access placement has not
een specifically described in the literature. The primary
bjective of this study is to analyze the short-term and
ong-term outcomes of patients undergoing AVF place-
ent in the presence of MetS. We hypothesize MetS will
egatively affect long-term hemodialysis access patency.
ETHODS
Study design. A database of patients undergoing pri-
ary hemodialysis access placement from 1999 to 2009 at
he Veterans Administration (VA) Connecticut Healthcare
ystem,West Haven, Connecticut, was queried. If a patient
ad undergone two or more access placement attempts
uring the study period, only data pertaining to the initial
peration were used. The study excluded access sites placed
n a patient’s lower extremity. Medical records were re-
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Volume 56, Number 6 Protack et al 1657viewed through December 2011 for follow-up data. The
Social Security Death Index was used to assist in determin-
ing postoperative mortality.
For each patient, demographics, comorbidities, and
perioperative outcomes were identified. Demographics in-
cluded age, sex, and race. Comorbidities included the
preoperative presence of myocardial infarction history, con-
gestive heart failure, atrial fibrillation, hypertension, DM,
hypothyroidism, cancer history, prior and current tobacco
usage, current hemodialysis, positive for human immuno-
deficiency virus (HIV), intravenous drug abuse, and hepa-
titis C. Medical records were reviewed for serum triglycer-
ide, high-density lipoprotein (HDL) cholesterol, total
cholesterol, hemoglobin A1c, height, and weight.
Procedures. Selection of hemodialysis access location
(forearm vs upper arm) and conduit choice (autogenous vs
nonautogenous) was left to the discretion of the surgeon.
Definitions. MetS was defined based on the presence
of three or more of the following five criteria: hypertension
(systolic blood pressure140 mmHg or diastolic pressure
90mmHg on three occasions during a 6-month period),
reduced HDL cholesterol (40 mg/dL for men, 50
mg/dL for women), elevated triglycerides (150 mg/
dL), impaired glucose control (110mg/dL fasting serum
glucose), and a body mass index (BMI) 30.0 kg/m2.
Primary patency, secondary patency, and survival were
Table I. Patient demographics and comorbidities
Variable
All patients
(N  187)
Demographics
Male sex, % 98
Age, mean  SD years 66.1  11.6
White race, % 70
Comorbidities, %
MI history 19
Congestive heart failure 25
Atrial fibrillation 12
COPD 12
Hypertension 98
DM 57
IDDM 11
NIDDM 47
Hypothyroidism 7
Tobacco usage
Past 33
Current 16
Cancer history 17
Current hemodialysis 39
HIV positivity 4
Intravenous drug abuse 7
Hepatitis C 13
Surgical variables, %
Prosthetic conduit 6
Forearm location 53
COPD, Chronic obstructive pulmonary disease; DM, diabetes mellitus; HI
MetS, metabolic syndrome; NIDDM, non-insulin-dependent diabetes mell
deviation.
aStatistically significant.defined using current Society for Vascular Surgery crite- cia.14 Primary patency was defined as the interval from the
ime of access placement until any intervention designed to
aintain or re-establish patency, access thrombosis, or the
ime of measurement of patency. Secondary patency was
efined as the interval from the time of access placement
ntil access abandonment, thrombosis, or the time of pa-
ency measurement, including interventions performed for
e-establishing functionality of thrombosed access. Patients
ith hemodialysis access that failed to mature were in-
luded in the final analysis.
Statistical analysis. Measured values are reported as
ercentages or means  standard deviations (SDs). Rates
or comorbidities, complications, and 30-day outcomes
ere compared between patients with MetS and without
etS (No MetS) by 2 test. Survival, primary patency, and
econdary patency were calculated using Kaplan-Meier
nalysis using the Gehan-Breslow test. Standard errors are
eported in Kaplan-Meier analyses. The Cox proportional
azards model was used to examine the associations be-
ween MetS and primary patency, secondary patency, and
urvival. Analyses were performed using JMP 9.0 software
SAS Institute, Cary, NC).
ESULTS
Patient population. During the study period, 187
emodialysis access sites were placed (Table I). The cohort
No MetS MetS
P(n  72) (n  115)
. . .
99 98 .85
6.9  12.4 65.7  11.0 .47
63 75 .075
11 24 .025
21 28 .29
10 14 .40
11 12 .83
96 99 .13
26 76 .0001a
10 12 .61
17 65 .0001a
7 8 .83
38 30 .26
21 12 .11
15 17 .71
40 38 .79
1 6 .12
7 8 .83
13 14 .78
7 6 .82
57 50 .39
an immunodeficiency virus; IDDM, insulin-dependent diabetes mellitus;
I, myocardial infarction; No MetS, no metabolic syndrome; SD, standard6
V, hum
itus; Monsisted of 184 men (98.4%). Patients were a mean age of
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December 20121658 Protack et al66 12 years (range, 35-90 years), and 131 (70%) were
white. The median follow-up was 4.2 years.
Comorbidities. Patients with MetS had a significantly
higher rate of myocardial infarction history (24% vs 11%;
P .025; Table I). The two groups (MetS vsNoMetS) had
equivalent rates of congestive heart failure (28% vs 21%;
P  .286), atrial fibrillation (14% vs 10%; P  .396),
hypertension (99% vs 96%; P .129), and chronic obstruc-
tive pulmonary disease (11% vs 12%; P  .826). MetS
patients were more likely to have DM (76% vs 26%; P 
.0001). Both groups had equivalent rates of hypothyroid-
ism (78% vs 69%; P  .824), documented past tobacco
usage (30% vs 38%; P .26), documented current tobacco
usage (12% vs 21%; P  .111), and cancer history (17% vs
15%; P  .705). No difference was identified with respect
to HIV positivity (6% vs 1%; P  .122), prior intravenous
drug abuse (8% vs 7%; P  .824), or hepatitis C (14% vs
13%; P  .782). The two groups had equivalent rates of
current hemodialysis usage (38% vs 40%; P  .783) as well
as prior peritoneal dialysis usage (0% vs 3%; P  .072).
The most common etiology for renal failure among all
patients was a combination of hypertension andDM (42%),
followed by hypertension alone (33%), DM alone (12%),
and polycystic kidney disease (5%). The remaining etiolo-
gies for renal failure included one to two occurrences of the
following: lithium toxicity, contrast-induced nephropathy,
HIV nephropathy, ciprofloxacin toxicity, cyclosporine tox-
icity, lupus, immunoglobulin A nephropathy, focal seg-
mental glomerulosclerosis, and membranoproliferative
glomerulonephritis.
The groups differed in their etiologies of renal failure.
As expected, the MetS patients had higher rates of DM-
induced renal failure (15.7% vs 5.5%; P  .029) and the
combination of hypertension- and DM-induced renal fail-
ure (53.9% vs 22.2%; P  .001). However, the No MetS
group had a higher rate of hypertension alone-induced
renal failure (59.7% vs 15.7%; P  .001). No difference
existed between groups with respect to polycystic kidney
disease or any of the other etiologies that existed in only
one or two patients.
MetS status. MetS was present in 115 patients (61%;
Table II. Components of MetS
Variable All patients
Serum triglyceride
Mean  SD mg/dL 155.2  7.2
150 mg/dL, % 39
Serum HDL cholesterol
Mean  SD mg/dL 40.2  1.3
40, 50 mg/dL, % 60
Hypertension, % 98
Elevated blood glucose, % 58
BMI 30 kg/m2, % 36
Total MetS score, mean  SD 2.9  0.09
BMI, Body mass index; HDL, high-density lipoprotein; MetS, metabolic syn
aStatistically significant.Table II). The distribution of MetS scores was 5 (10%), 4 r23%), 3 (28%), 2 (25%), 1 (12%), and 0 (1%). Of the five
actors determining MetS, the most prevalent was hyper-
ension (98%), 60% had serumHDL cholesterol levels40
g/d, 58% had an elevated fasting blood glucose, 39% had
erum triglyceride levels150mg/dL, and 36% had a BMI
30 kg/m2. Between groups, the MetS group exhibited
reater rates of serum triglyceride 150 mg/dL (54% vs
4%; P  .0001), serum HDL cholesterol 40 mg/dL
85% vs 19%; P .0001), BMI30 kg/m2 (54% vs 7%; P
0001), and elevated fasting blood glucose (78% vs 26%; P 
0001).However, the two groups had equivalent rates of hyper-
ension (MetS, 99%; No MetS, 96%; P  .129). The most
ommon triad of factors, which was present in 64% of theMetS
atients, was hypertension (99%), decreased HDL cholesterol
85%), and elevated fasting blood glucose (78%).
Procedures. Of the hemodialysis access sites placed, 175
94%) were autogenous, whereas 6% were prosthetic. No
ifference in conduit type was identified between groups
MetS, 6%; No MetS, 7%; P  .817; Table III). Ninety-nine
53%) of the access sites placed were located in the forearm.
o difference in upper extremity location was identified be-
ween groups (MetS, 57%; No MetS, 50%; P .388).
Outcomes. The 30-day survival rate was 99% (two
eaths). The median time until death was 4.15 years (95%
onfidence interval [CI], 3.19-5.07 years). Patients with
etS exhibited increased mortality during long-term
ollow-up, with a median survival of 3.63 years vs 5.07 years
or NoMetS (P .019; Fig 1). The 6-, 12-, and 24-month
urvival rates were 91%, 83%, and 69% for MetS patients,
espectively, and 97%, 94%, and 82% for No MetS patients,
able III. Surgical outcomes
0-day outcomes
All patients
(%)
No MetS
(%)
MetS
(%) P
rimary patency failure 5 4 5 0.75
econdary patency failure 4 4 3 0.81
eath 0.5 1 0 0.21
etS, Metabolic syndrome; No MetS, no metabolic syndrome.
No MetS MetS P
110.7  7.8 182.2  9.7 .0001a
14 54 .0001a
51.2  2.6 33.6  0.9 .0001a
19 85 .0001a
96 99 .01a
26 78 .0001a
7 54 .0001a
1.6  0.06 3.7  0.07 .0001a
e; No MetS, no metabolic syndrome; SD, standard deviation.dromespectively (P  .019).
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Volume 56, Number 6 Protack et al 1659The 30-day primary patency rate was 93.1%. The me-
dian time until failure of primary patency was 0.460 years
(95% CI, 0.37-0.58 years). No difference was demon-
strated between groups with respect to primary patency.
Median time to primary patency failure was 0.436 years for
MetS and 0.555 years for No MetS (P  .26; Fig 2). The
6-, 12-, and 24-month freedom from primary patency
failure was 43%, 19%, and 9%, respectively, for MetS and
54%, 29%, and 5%, respectively, for No MetS (P  .255).
Most access failures occurred in the venous outflow (91%),
with 18% of failures having an arterial lesion and 9% having
an arterial and a venous lesion; there was no difference
between patients with and without MetS.
The 30-day secondary patency rate was 94.7%. The
median time until failure of secondary patency was 1.180
years (95% CI, 0.73-1.86 years). MetS patients demon-
strated failure of secondary patency at 0.720 years vs 1.940
years for No MetS patients (P  .024; Fig 3). The 6-, 12-,
and 24-month freedom from secondary patency failure was
61%, 41%, and 33%, respectively, for MetS, and 79%, 68%,
and 47%, respectively, for No MetS (P  .024).
Influence of MetS score. MetS score severity was
associated with unfavorable outcomes. Survival rates were
decreased in MetS patients with a score of 4 or 5 compared
with those with a score of 3 or 0 to 2, with median survivals
of 2.87, 4.31, and 5.07 years, respectively (P .0143), and
median time to failure of secondary patency of 0.58, 2.67,
and 1.94 years, respectively (P  .0065). No difference
Fig 1. Survival rates for all patients at 6, 12, and 24 m
analysis showed patients with metabolic syndrome (Me
failure compared with patients without MetS (No-MetS
exceed 10% at all time intervals analyzed.existed between groups with respect to primary patency. pHazard analysis. Of the patient demographics, comor-
idities, and surgical variables, the only factor identified as having
n effect on primary patency was hepatitis C (hazard ratio [HR],
.47;95%CI,0.21-0.96;Table IV).For secondarypatency,only
he presence of MetS was identified as having an effect (HR,
.65; 95% CI, 1.05-2.62; Table V). For overall survival, the
resence of MetS (HR, 1.53, 95% CI, 1.01-2.35), congestive
eart failure (HR,1.61,95%CI,1.05-2.44), andatrialfibrillation
HR, 1.83, 95% CI, 1.03-3.08) were deleterious, whereas a
istory of intravenous drug abuse (HR, 0.34, 0.10-0.88) and
ypertension (HR, 0.21, 95% CI, 0.07-0.89) were protective
Table VI).
A hazard analysis consisting of only the five individual
actors constituting MetS revealed elevated blood glucose
nd elevated BMI as independent risk factors for death or
umulative patency failure. In particular, DM was a signif-
cant risk factor for death (hazard ratio [HR], 1.73; P 
008) and cumulative patency failure (HR, 1.62; P .032).
n elevated BMI 30 kg/m2 was a significant risk factor
nly for primary patency failure (HR, 1.63; P  .029).
ISCUSSION
In this study,we characterized the prevalence ofMetS and
ssessed its relation to the short-termand long-termoutcomes
or 187 patients undergoing first-time hemodialysis access
lacement in the upper extremity. MetS was highly prevalent
n our patient population, at 61%, which is similar to the
revalence of MetS found by Gorter et al15 for patients with
s were 93%, 87%, and 73%, respectively. Kaplan-Meier
perienced decreased freedom from secondary patency
or bars are omitted for clarity. Standard error did notonth
tS) ex
). Erreripheral arterial disease. To our knowledge, no other study
JOURNAL OF VASCULAR SURGERY
December 20121660 Protack et alFig 2. Freedom from primary patency failure for all patients at 6, 12, and 24 months was 47%, 24%, and
8%, respectively. No difference was identified between groups. Error bars are omitted for clarity. Standard error
did not exceed 10% at all time intervals analyzed. MetS, Metabolic syndrome; No-MetS, no metabolic syndrome.Fig 3. Freedom from secondary patency failure for all patients at 6, 12, and 24 months was 69%, 53%, and 38%,
respectively. By Kaplan-Meier analysis, patients with metabolic syndrome (MetS) experienced decreased freedom from
secondary patency failure compared with patients without MetS (No-MetS). Error bars are omitted for clarity. Standard
error did not exceed 10% at all time intervals analyzed.
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aStatistically significant.
syndrome; MI, myocardial infarction.
aStatistically significant.
syndrome; MI, myocardial infarction.
aStatistically significant.
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emodialysis access placement or the long-term outcomes in
hese patients. MetS had no influence on primary patency
ates in this study; however, MetS patients had significantly
reater mortality and secondary patency failure events. The
o MetS patients exhibited a median survival time of 1.44
ears greater and a freedom from secondary patency failure
hat was more than doubled. Although the groups differed in
ong-term patency rates, we did not identify differences be-
ween them for the etiology of access failure.
MetS results in a state of platelet dysfunction, endothe-
ial dysfunction, and a prothrombotic environment. Several
nflammatory markers are increased in MetS: monocyte
hemotactant protein (MCP)-1, tumor necrosis factor-,
nterleukin (IL)-6, IL-8, and plasminogen activator inhib-
tor type (PAI)-1.4 Before the conception of MetS, De
archi et al12 found patients who presented with fistula
ysfunction postoperatively had elevated levels of IL-6,
CP-1, PAI-1, protein C, and protein S compared with
atients without fistula dysfunction. Not surprisingly, these
atients also had elevated cholesterol and triglyceride levels
nd lower HDL levels. Because IL-6, MCP-1, PAI-1, and
yslipidemia are hallmark characteristics of MetS, our long-
erm findings of AVF failure are consistent with their short-
erm fistula dysfunction findings.
Several definitions of MetS are currently in use.16-19 As we
ave previously described,8 we substituted BMI30 kg/m2 for
runcal obesity. Owing to the retrospective design of our study,
e were unable to obtain abdominal circumference measure-
ents from each patient because they are not routinely obtained
reoperatively. We are confident with our identification of No
etS status in the 72 patients is due to a true absence of the
yndrome rather than to inadequate data collection, because the
Aelectronic recordallowscapture andeasy accessof all patients’
aboratory values. For instance, 180 of the 187 patients (96.3%)
ad preoperative serum triglyceride values, 179 (95.7%) had
reoperative HDL values, and a preoperative BMI had been
alculated for 181 (96.8%).All patients (100%)were identified as
aving the presence or absence of elevated plasma glucose (from
erum glucose of HbA1c measurements) and hypertension. Of
hose patients with missing data points, only four (2.1%) were
ound not to have MetS; therefore, the absence of MetS can be
ssumed to result from a lack of the syndrome rather than from
navailable data.
Huber et al20 conducted a 34-study systematic review
or primary and secondary patency outcomes for autogen-
us and prosthetic conduits. The primary patency for au-
ogenous-only conduits was 72% and 51% at 6 and 18
onths, respectively, and secondary patency rates were 86%
nd 77%, respectively.20 Their primary and secondary pa-
ency outcomes were superior to our primary patency out-
omes for autogenous-only conduits of 48% and 12% at 6
nd 18 months, respectively, and secondary patency of 70%
nd 47%. It is possible that the reduced rates of patency in
ur patients may reflect our study reporting an exclusively
eteran population, with its high rate of comorbidities as
ell as the observation that half of our patients are notTable IV. Cox proportional hazard analysis: factors
affecting primary patency failure
Factor HR (95% CI) P
MetS present 1.09 (0.74-1.61) .65
MI history 0.96 (0.55-1.61) .89
Congestive heart failure 1.34 (0.85-2.06) .20
Atrial fibrillation 1.22 (0.67-2.08) .50
COPD 0.99 (0.53-1.72) .97
HIV positivity 2.33 (0.80-5.69) .11
Intravenous drug abuse 0.90 (0.38-2.02) .81
Hepatitis C 0.47 (0.21-0.96) .04a
Hypertension 1.32 (0.45-5.68) .65
Cancer history 0.77 (0.46-1.26) .31
Upper arm 0.79 (0.54-1.16) .23
Arteriovenous graft 0.94 (0.42-1.94) .88
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
HIV, human immunodeficiency virus; HR, hazard ratio; MetS, metabolicTable V. Cox proportional hazard analysis: factors
affecting secondary patency failure
Factor HR (95% CI) P
MetS present 1.65 (1.05-2.62) .03a
MI history 0.83 (0.40-1.60) .58
Congestive heart failure 0.93 (0.54-1.55) .80
Atrial fibrillation 1.47 (0.77-2.62) .23
COPD 1.39 (0.65-2.68) .37
HIV positivity 0.35 (0.09-1.12) .08
Intravenous drug abuse 1.66 (0.60-4.23) .32
Hepatitis C 0.44 (0.16-1.06) .07
Hypertension 1.11 (0.30-7.28) .90
Cancer history 1.05 (0.57-1.86) .87
Upper arm 0.81 (0.51-1.28) .36
Arteriovenous graft 1.57 (0.63-3.49) .32
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
HIV, human immunodeficiency virus; HR, hazard ratio; MetS, metabolicTable VI. Cox proportional hazard analysis: factors
affecting survival
Factor HR (95% CI) P
MetS present 1.53 (1.01-2.35) .045a
MI history 1.18 (0.70-1.90) .52
Congestive heart failure 1.61 (1.04-2.44) .031a
Atrial fibrillation 1.83 (1.03-3.08) .040a
COPD 0.81 (0.41-1.46) .51
HIV positivity 0.32 (0.02-1.53) .18
Intravenous drug abuse 0.34 (0.10-0.88) .024a
Hepatitis C 0.62 (0.26-1.26) .20
Hypertension 0.21 (0.07-0.89) .037a
Cancer history 1.11 (0.65-1.82) .69
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
HIV, human immunodeficiency virus; HR, hazard ratio; MetS, metaboliceceiving their dialysis and access care within the VA sys-
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December 20121662 Protack et altem.21,22 In addition, with only 6% of our patients receiving
prosthetic conduits during AVF creation, we were unable to
compare our patency outcomes for AV grafts alone due to the
low sample size and increased standard error.
Our study was conducted at a VAMedical Center, which
in prior investigations21,22 has been identified as having a
“high-risk” surgical patient population for vascular surgery
interventions, which is consistent with our observed high
mortality rate (Fig 1). Snyder et al23 conducted a retrospective
review examining the 1-year and 2-year primary and second-
ary patency outcomes in 64AVgrafts and 50AVFs performed
at a VA Medical Center.23 For AVFs alone, the 1-year and
2-year primary patency outcomes were 44% and 37%, respec-
tively, and secondary patency outcomes were 75% and 72%,
respectively. It is possible that the large number of comorbid
conditions associated with the veteran population requires
diagnostic and therapeutic use of the patients’ veins, dimin-
ishing their suitability for access.
The data presented in this study represent a retrospec-
tive review of patients undergoing hemodialysis access at a
single institution during a 10-year period, and as such, our
study has all of the problems associated with retrospective
reviews. A potential further limitation is the continual
improvement in the medical management of patients with
MetS, which has evolved during our study period. Future
studies examining the outcomes of hemodialysis access in
patients with MetS may define the presumed benefits due
to medical management of this disease.
CONCLUSIONS
MetS is prevalent among patients undergoing hemodial-
ysis access placement. MetS is associated with several proin-
flammatory and prothrombotic factors, which have previously
been shown to contribute to AVF dysfunction. Patients un-
dergoing hemodialysis access placement in the presence of
MetS experience greater mortality and decreased secondary
patency rates. We believe that patients with MetS form a
high-risk group that needs intensive surveillance protocols.
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